CareDx Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
CDNA$80.77-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the and
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(16,659) | $(23,749) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 13,344 | 13,754 |
| Revaluation of common stock warrant liability to estimated fair value | — | (7) |
| Depreciation and amortization | 3,821 | 3,427 |
| Asset impairments and write-downs | — | 1,000 |
| Amortization of right-of-use assets | 1,402 | 1,337 |
| Unrealized loss on long-term marketable equity securities | — | 905 |
| Revaluation of contingent consideration to estimated fair value | 319 | 364 |
| Amortization of premium and accretion of discount on short-term marketable securities, net | 1,451 | (773) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (9,199) | 7,664 |
| Inventory | (1,274) | 1,217 |
| Prepaid and other assets | 108 | 1,515 |
| Operating leases liabilities, net | (1,372) | (1,333) |
| Accounts payable | (2,897) | 2,590 |
| Accrued compensation | (4,820) | (4,888) |
| Accrued and other liabilities | 557 | (2,352) |
| Change in deferred taxes | (93) | — |
| Net cash (used in) provided by operating activities | (15,312) | 671 |
| Investing activities: | ||
| Acquisitions of business, net of cash acquired | — | (4,562) |
| Purchases of short-term marketable securities | (57,746) | (86,310) |
| Maturities of short-term marketable securities | 86,893 | 78,972 |
| Purchase of corporate equity securities | — | (100) |
| Additions of capital expenditures | (1,487) | (2,771) |
| Net cash provided by (used in) investing activities | 27,660 | (14,771) |
| Financing activities: | ||
| Proceeds from issuance of common stock under employee stock purchase plan | 532 | 456 |
| Taxes paid related to net share settlement of restricted stock units | (668) | (656) |
| Proceeds from exercise of stock options | 8 | 2 |
| Payment of contingent consideration | (625) | (250) |
| Repurchase and retirement of common stock | (522) | (690) |
| Net cash used in financing activities | (1,275) | (1,138) |
| Effect of exchange rate changes on cash and cash equivalents | 26 | (25) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 11,099 | (15,263) |
| Cash, cash equivalents and restricted cash at beginning of period | 82,783 | 90,443 |
| Cash, cash equivalents and restricted cash at end of period | $93,882 | $75,180 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.